You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTranylcypromine
Accession NumberDB00752  (APRD00645)
TypeSmall Molecule
GroupsApproved
Description

A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311)

Structure
Thumb
Synonyms
Parnate
Tranilcipromina
Transamine
Tranylcypromin
Tranylcypromine
Tranylcyprominum
External Identifiers Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Parnatetablet, film coated10 mg/1oralCovis Pharmaceuticals Inc2013-01-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Parnatetablet10 mgoralGlaxosmithkline Inc1992-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Parnatetablet, film coated10 mg/1oralConcordia Pharmaceuticals Inc.2013-01-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tranylcypromine Sulfatetablet, film coated10 mg/1oralActavis Pharma, Inc.2016-02-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tranylcypromine Sulfatetablet10 mg/1oralRising Pharmaceuticals, Inc.2012-01-09Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tranylcypromine Sulfatetablet10 mg/1oralREMEDYREPACK INC.2014-04-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Tranylcypromine Sulfatetablet10 mg/1oralPar Pharmaceutical, Inc.2006-06-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tranylcypromine Sulfatetablet10 mg/1oralGolden State Medical Supply, Inc.2012-02-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
JatrosomAristo Pharma
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Tranylcypromine Sulfate
ThumbNot applicableDBSALT000960
Categories
UNII3E3V44J4Z9
CAS number155-09-9
WeightAverage: 133.1903
Monoisotopic: 133.089149357
Chemical FormulaC9H11N
InChI KeyInChIKey=AELCINSCMGFISI-YGPZHTELSA-N
InChI
InChI=1S/C9H11N/c10-9-6-8(9)7-4-2-1-3-5-7/h1-5,8-9H,6,10H2/t8?,9-/m1/s1
IUPAC Name
(1R)-2-phenylcyclopropan-1-amine
SMILES
N[C@@H]1CC1C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.
KingdomOrganic compounds
Super ClassOrganonitrogen compounds
ClassAmines
Sub ClassAralkylamines
Direct ParentAralkylamines
Alternative Parents
Substituents
  • Aralkylamine
  • Benzenoid
  • Monocyclic benzene moiety
  • Hydrocarbon derivative
  • Primary amine
  • Primary aliphatic amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of major depressive episode without melancholia.
PharmacodynamicsTranylcypromine belongs to a class of antidepressants called monoamine oxidase inhibitors (MAOIs). Tranylcypromine is a non-hydrazine monoamine oxidase inhibitor with a rapid onset of activity. MAO is an enzyme that catalyzes the oxidative deamination of a number of amines, including serotonin, norepinephrine, epinephrine, and dopamine. Two isoforms of MAO, A and B, are found in the body. MAO-A is mainly found within cells located in the periphery and catalyzes the breakdown of serotonin, norepinephrine, epinephrine, dopamine and tyramine. MAO-B acts on phenylethylamine, norepinephrine, epinephrine, dopamine and tyramine, is localized extracellularly and is found predominantly in the brain. While the mechanism of MAOIs is still unclear, it is thought that they act by increasing free serotonin and norepinephrine concentrations and/or by altering the concentrations of other amines in the CNS. It has been postulated that depression is caused by low levels of serotonin and/or norepinephrine and that increasing serotonergic and norepinephrinergic neurotransmission results in relief of depressive symptoms. MAO A inhibition is thought to be more relevant to antidepressant activity than MAO B inhibition. Selective MAO B inhibitors, such as selegiline, have no antidepressant effects.
Mechanism of actionTranylcypromine irreversibly and nonselectively inhibits monoamine oxidase (MAO). Within neurons, MAO appears to regulate the levels of monoamines released upon synaptic firing. Since depression is associated with low levels of monoamines, the inhibition of MAO serves to ease depressive symptoms, as this results in an increase in the concentrations of these amines within the CNS.
AbsorptionInterindividual variability in absorption. May be biphasic in some individuals. Peak plasma concentrations occur in one hour following oral administration with a secondary peak occurring within 2-3 hours. Biphasic absorption may represent different rates of absorption of the stereoisomers of the drug, though additional studies are required to confirm this.
Volume of distribution

1.1-5.7 L/kg

Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationNot Available
Half life1.5-3.2 hours in patients with normal renal and hepatic function
ClearanceNot Available
ToxicityIn overdosage, some patients exhibit insomnia, restlessness and anxiety, progressing in severe cases to agitation, mental confusion and incoherence. Hypotension, dizziness, weakness and drowsiness may occur, progressing in severe cases to extreme dizziness and shock. A few patients have displayed hypertension with severe headache and other symptoms. Rare instances have been reported in which hypertension was accompanied by twitching or myoclonic fibrillation of skeletal muscles with hyperpyrexia, sometimes progressing to generalized rigidity and coma.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9383
Caco-2 permeable+0.7935
P-glycoprotein substrateNon-substrate0.8349
P-glycoprotein inhibitor INon-inhibitor0.9566
P-glycoprotein inhibitor IINon-inhibitor0.9899
Renal organic cation transporterNon-inhibitor0.8659
CYP450 2C9 substrateNon-substrate0.8439
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateNon-substrate0.7604
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.8659
CYP450 2D6 inhibitorNon-inhibitor0.7879
CYP450 2C19 inhibitorInhibitor0.8748
CYP450 3A4 inhibitorNon-inhibitor0.9372
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6942
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.6686
BiodegradationReady biodegradable0.5525
Rat acute toxicity2.4266 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9807
hERG inhibition (predictor II)Non-inhibitor0.9378
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Glaxosmithkline
  • Par pharmaceutical inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral10 mg
Tablet, film coatedoral10 mg/1
Tabletoral10 mg/1
Prices
Unit descriptionCostUnit
Parnate 10 mg tablet1.64USD tablet
Tranylcypromine Sulfate 10 mg tablet1.3USD tablet
Tranylcypromine sulf 10 mg tablet1.25USD tablet
Parnate 10 mg Tablet0.41USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point79-80 °C at 1.50E+00 mm HgNot Available
water solubility4.86E+004 mg/LNot Available
logP1.58HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility1.49 mg/mLALOGPS
logP1.5ALOGPS
logP1.34ChemAxon
logS-1.9ALOGPS
pKa (Strongest Basic)9.62ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area26.02 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity41.7 m3·mol-1ChemAxon
Polarizability15.33 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
MSMass Spectrum (Electron Ionization)splash10-hz00000000-a7221eab5a5f5d286c2aView in MoNA
References
Synthesis ReferenceNot Available
General References
  1. Frieling H, Bleich S: Tranylcypromine: new perspectives on an “old” drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73. Pubmed
  2. Nolen WA: [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression] Ned Tijdschr Geneeskd. 2003 Oct 4;147(40):1940-3. Pubmed
External Links
ATC CodesN06AF04
AHFS Codes
  • 28:16.04.12
PDB Entries
FDA labelDownload (152 KB)
MSDSDownload (38.3 KB)
Interactions
Drug Interactions
Drug
AcarboseTranylcypromine may increase the hypoglycemic activities of Acarbose.
AcebutololTranylcypromine may increase the orthostatic hypotensive activities of Acebutolol.
AcepromazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Acepromazine.
AcetazolamideTranylcypromine may increase the orthostatic hypotensive activities of Acetazolamide.
AcetophenazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Acetophenazine.
AclidiniumAclidinium may increase the anticholinergic activities of Tranylcypromine.
AgomelatineThe serum concentration of Agomelatine can be increased when it is combined with Tranylcypromine.
AlbiglutideTranylcypromine may increase the hypoglycemic activities of Albiglutide.
AlfentanilAlfentanil may increase the serotonergic activities of Tranylcypromine.
AlfuzosinTranylcypromine may increase the orthostatic hypotensive activities of Alfuzosin.
AliskirenTranylcypromine may increase the hypotensive activities of Aliskiren.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Tranylcypromine.
AlogliptinTranylcypromine may increase the hypoglycemic activities of Alogliptin.
AltretamineAltretamine may increase the orthostatic hypotensive activities of Tranylcypromine.
AmantadineTranylcypromine may increase the orthostatic hypotensive activities of Amantadine.
AmilorideTranylcypromine may increase the orthostatic hypotensive activities of Amiloride.
AmisulprideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Amisulpride.
AmitriptylineTranylcypromine may increase the serotonergic activities of Amitriptyline.
AmlodipineTranylcypromine may increase the hypotensive activities of Amlodipine.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Tranylcypromine.
AmoxapineTranylcypromine may increase the serotonergic activities of Amoxapine.
AmphetamineTranylcypromine may increase the hypertensive activities of Amphetamine.
AnagrelideTranylcypromine may increase the orthostatic hypotensive activities of Anagrelide.
ApomorphineTranylcypromine may increase the orthostatic hypotensive activities of Apomorphine.
ApraclonidineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Apraclonidine.
ArformoterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Arformoterol.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Tranylcypromine.
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Tranylcypromine resulting in a loss in efficacy.
ArticaineTranylcypromine may increase the hypertensive activities of Articaine.
AsenapineTranylcypromine may increase the orthostatic hypotensive activities of Asenapine.
AtenololTranylcypromine may increase the orthostatic hypotensive activities of Atenolol.
AtomoxetineTranylcypromine may increase the central neurotoxic activities of Atomoxetine.
AtropineTranylcypromine may increase the hypertensive activities of Atropine.
Azilsartan medoxomilTranylcypromine may increase the orthostatic hypotensive activities of Azilsartan medoxomil.
BenazeprilTranylcypromine may increase the orthostatic hypotensive activities of Benazepril.
BendroflumethiazideTranylcypromine may increase the orthostatic hypotensive activities of Bendroflumethiazide.
BenzphetamineTranylcypromine may increase the hypertensive activities of Benzphetamine.
BenzquinamideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Benzquinamide.
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Tranylcypromine.
BetaxololTranylcypromine may increase the orthostatic hypotensive activities of Betaxolol.
BezafibrateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bezafibrate.
BisoprololTranylcypromine may increase the orthostatic hypotensive activities of Bisoprolol.
BortezomibThe metabolism of Bortezomib can be decreased when combined with Tranylcypromine.
Botulinum Toxin Type ATranylcypromine may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BTranylcypromine may increase the anticholinergic activities of Botulinum Toxin Type B.
BretyliumTranylcypromine may increase the orthostatic hypotensive activities of Bretylium.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Tranylcypromine.
BrimonidineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Brimonidine.
BromocriptineTranylcypromine may increase the orthostatic hypotensive activities of Bromocriptine.
BumetanideTranylcypromine may increase the orthostatic hypotensive activities of Bumetanide.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Tranylcypromine.
BupropionTranylcypromine may increase the hypertensive activities of Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Tranylcypromine.
CabergolineTranylcypromine may increase the orthostatic hypotensive activities of Cabergoline.
CanagliflozinTranylcypromine may increase the hypoglycemic activities of Canagliflozin.
CandesartanTranylcypromine may increase the orthostatic hypotensive activities of Candesartan.
CaptoprilTranylcypromine may increase the orthostatic hypotensive activities of Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tranylcypromine.
CarbidopaThe risk or severity of adverse effects can be increased when Carbidopa is combined with Tranylcypromine.
CarphenazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Carphenazine.
CarteololTranylcypromine may increase the orthostatic hypotensive activities of Carteolol.
CarvedilolTranylcypromine may increase the orthostatic hypotensive activities of Carvedilol.
CathinoneTranylcypromine may increase the hypertensive activities of Cathinone.
ChlordiazepoxideTranylcypromine may increase the orthostatic hypotensive activities of Chlordiazepoxide.
ChlormezanoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chlormezanone.
ChlorothiazideTranylcypromine may increase the orthostatic hypotensive activities of Chlorothiazide.
ChlorpromazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chlorpromazine.
ChlorpropamideTranylcypromine may increase the hypoglycemic activities of Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chlorprothixene.
ChlorthalidoneTranylcypromine may increase the orthostatic hypotensive activities of Chlorthalidone.
CilazaprilTranylcypromine may increase the orthostatic hypotensive activities of Cilazapril.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Tranylcypromine.
Cimetropium BromideTranylcypromine may increase the anticholinergic activities of Cimetropium Bromide.
CitalopramTranylcypromine may increase the serotonergic activities of Citalopram.
ClemastineTranylcypromine may increase the anticholinergic activities of Clemastine.
ClevidipineTranylcypromine may increase the hypotensive activities of Clevidipine.
ClidiniumTranylcypromine may increase the orthostatic hypotensive activities of Clidinium.
ClomipramineTranylcypromine may increase the serotonergic activities of Clomipramine.
ClonidineTranylcypromine may increase the orthostatic hypotensive activities of Clonidine.
ClopidogrelThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Tranylcypromine resulting in a loss in efficacy.
ClorazepateTranylcypromine may increase the orthostatic hypotensive activities of Clorazepate.
ClozapineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Clozapine.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Tranylcypromine.
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Tranylcypromine.
CyproheptadineTranylcypromine may increase the anticholinergic activities of Cyproheptadine.
DacarbazineTranylcypromine may increase the orthostatic hypotensive activities of Dacarbazine.
DapagliflozinTranylcypromine may increase the hypoglycemic activities of Dapagliflozin.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Tranylcypromine.
DesipramineTranylcypromine may increase the serotonergic activities of Desipramine.
DesvenlafaxineTranylcypromine may increase the serotonergic activities of Desvenlafaxine.
DexmedetomidineTranylcypromine may increase the orthostatic hypotensive activities of Dexmedetomidine.
DexmethylphenidateTranylcypromine may increase the hypertensive activities of Dexmethylphenidate.
DextroamphetamineTranylcypromine may increase the hypertensive activities of Dextroamphetamine.
DextromethorphanTranylcypromine may increase the serotonergic activities of Dextromethorphan.
DiazoxideTranylcypromine may increase the orthostatic hypotensive activities of Diazoxide.
DiclofenamideTranylcypromine may increase the orthostatic hypotensive activities of Diclofenamide.
DiethylpropionTranylcypromine may increase the hypertensive activities of Diethylpropion.
DiltiazemTranylcypromine may increase the hypotensive activities of Diltiazem.
DisopyramideTranylcypromine may increase the hypoglycemic activities of Disopyramide.
DomperidoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Domperidone.
DoxapramTranylcypromine may increase the hypertensive activities of Doxapram.
DoxazosinTranylcypromine may increase the orthostatic hypotensive activities of Doxazosin.
DoxepinTranylcypromine may increase the serotonergic activities of Doxepin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Tranylcypromine.
DoxylamineTranylcypromine may increase the anticholinergic activities of Doxylamine.
DronabinolTranylcypromine may increase the orthostatic hypotensive activities of Dronabinol.
DroperidolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Droperidol.
DulaglutideTranylcypromine may increase the hypoglycemic activities of Dulaglutide.
DuloxetineTranylcypromine may increase the serotonergic activities of Duloxetine.
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Tranylcypromine.
EluxadolineTranylcypromine may increase the activities of Eluxadoline.
EmpagliflozinTranylcypromine may increase the hypoglycemic activities of Empagliflozin.
EnalaprilTranylcypromine may increase the orthostatic hypotensive activities of Enalapril.
EnalaprilatTranylcypromine may increase the orthostatic hypotensive activities of Enalaprilat.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Tranylcypromine.
EphedrineTranylcypromine may increase the hypertensive activities of Ephedrine.
EpinephrineTranylcypromine may increase the hypertensive activities of Epinephrine.
EplerenoneTranylcypromine may increase the orthostatic hypotensive activities of Eplerenone.
EprosartanTranylcypromine may increase the orthostatic hypotensive activities of Eprosartan.
ErythromycinTranylcypromine may increase the hypoglycemic activities of Erythromycin.
EscitalopramTranylcypromine may increase the serotonergic activities of Escitalopram.
EsmololTranylcypromine may increase the orthostatic hypotensive activities of Esmolol.
Ethacrynic acidTranylcypromine may increase the orthostatic hypotensive activities of Ethacrynic acid.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Tranylcypromine.
ExenatideTranylcypromine may increase the hypoglycemic activities of Exenatide.
FelodipineTranylcypromine may increase the hypotensive activities of Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fencamfamine.
FenoterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fenoterol.
FentanylFentanyl may increase the serotonergic activities of Tranylcypromine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tranylcypromine.
FluoxetineTranylcypromine may increase the serotonergic activities of Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fluphenazine.
FluspirileneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Fluticasone Propionate.
FluvoxamineTranylcypromine may increase the serotonergic activities of Fluvoxamine.
FormoterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Formoterol.
FosinoprilTranylcypromine may increase the orthostatic hypotensive activities of Fosinopril.
FurosemideTranylcypromine may increase the orthostatic hypotensive activities of Furosemide.
GliclazideTranylcypromine may increase the hypoglycemic activities of Gliclazide.
GlimepirideTranylcypromine may increase the hypoglycemic activities of Glimepiride.
GlipizideTranylcypromine may increase the hypoglycemic activities of Glipizide.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Glucagon recombinant.
GlyburideTranylcypromine may increase the hypoglycemic activities of Glyburide.
GlycopyrrolateTranylcypromine may increase the orthostatic hypotensive activities of Glycopyrrolate.
GranisetronGranisetron may increase the serotonergic activities of Tranylcypromine.
GuanfacineTranylcypromine may increase the orthostatic hypotensive activities of Guanfacine.
HaloperidolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Haloperidol.
HydralazineTranylcypromine may increase the orthostatic hypotensive activities of Hydralazine.
HydrochlorothiazideTranylcypromine may increase the orthostatic hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Hydrocodone.
HydromorphoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Hydromorphone.
IloperidoneTranylcypromine may increase the orthostatic hypotensive activities of Iloperidone.
ImipramineTranylcypromine may increase the serotonergic activities of Imipramine.
IndacaterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Indacaterol.
IndapamideTranylcypromine may increase the orthostatic hypotensive activities of Indapamide.
inhaled insulinTranylcypromine may increase the hypoglycemic activities of inhaled insulin.
Insulin AspartTranylcypromine may increase the hypoglycemic activities of Insulin Aspart.
Insulin degludecTranylcypromine may increase the hypoglycemic activities of Insulin degludec.
Insulin DetemirTranylcypromine may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineTranylcypromine may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineTranylcypromine may increase the hypoglycemic activities of Insulin Glulisine.
Insulin LisproTranylcypromine may increase the hypoglycemic activities of Insulin Lispro.
Insulin RegularTranylcypromine may increase the hypoglycemic activities of Insulin Regular.
Ipratropium bromideIpratropium bromide may increase the anticholinergic activities of Tranylcypromine.
IrbesartanTranylcypromine may increase the orthostatic hypotensive activities of Irbesartan.
IsocarboxazidTranylcypromine may increase the orthostatic hypotensive activities of Isocarboxazid.
IsomethepteneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Isometheptene.
IsradipineTranylcypromine may increase the hypotensive activities of Isradipine.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Tranylcypromine.
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Tranylcypromine.
LabetalolTranylcypromine may increase the orthostatic hypotensive activities of Labetalol.
LanreotideTranylcypromine may increase the hypoglycemic activities of Lanreotide.
LevobunololTranylcypromine may increase the orthostatic hypotensive activities of Levobunolol.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Tranylcypromine.
LevomilnacipranTranylcypromine may increase the serotonergic activities of Levomilnacipran.
LevonordefrinTranylcypromine may increase the hypertensive activities of Levonordefrin.
LinezolidThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Linezolid.
LiraglutideTranylcypromine may increase the hypoglycemic activities of Liraglutide.
LisdexamfetamineTranylcypromine may increase the hypertensive activities of Lisdexamfetamine.
LisinoprilTranylcypromine may increase the orthostatic hypotensive activities of Lisinopril.
LithiumThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lithium.
LosartanTranylcypromine may increase the orthostatic hypotensive activities of Losartan.
LoxapineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Loxapine.
LurasidoneTranylcypromine may increase the orthostatic hypotensive activities of Lurasidone.
MannitolTranylcypromine may increase the orthostatic hypotensive activities of Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Tranylcypromine.
MecamylamineTranylcypromine may increase the orthostatic hypotensive activities of Mecamylamine.
MecaserminTranylcypromine may increase the hypoglycemic activities of Mecasermin.
MepivacaineTranylcypromine may increase the hypertensive activities of Mepivacaine.
MequitazineTranylcypromine may increase the anticholinergic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Mesoridazine.
MetforminTranylcypromine may increase the hypoglycemic activities of Metformin.
MethadoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methadone.
MethamphetamineTranylcypromine may increase the hypertensive activities of Methamphetamine.
MethazolamideTranylcypromine may increase the orthostatic hypotensive activities of Methazolamide.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methotrimeprazine.
MethyclothiazideTranylcypromine may increase the orthostatic hypotensive activities of Methyclothiazide.
MethyldopaThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methyldopa.
Methylene blueTranylcypromine may increase the serotonergic activities of Methylene blue.
MethylphenidateTranylcypromine may increase the hypertensive activities of Methylphenidate.
MetipranololTranylcypromine may increase the orthostatic hypotensive activities of Metipranolol.
MetoclopramideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Metoclopramide.
MetolazoneTranylcypromine may increase the orthostatic hypotensive activities of Metolazone.
MetoprololTranylcypromine may increase the orthostatic hypotensive activities of Metoprolol.
MianserinTranylcypromine may increase the neurotoxic activities of Mianserin.
MidodrineTranylcypromine may increase the hypertensive activities of Midodrine.
MifepristoneTranylcypromine may increase the hypoglycemic activities of Mifepristone.
MiglitolTranylcypromine may increase the hypoglycemic activities of Miglitol.
MilnacipranTranylcypromine may increase the serotonergic activities of Milnacipran.
MinoxidilTranylcypromine may increase the orthostatic hypotensive activities of Minoxidil.
MirabegronThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Mirabegron.
MirtazapineTranylcypromine may increase the central neurotoxic activities of Mirtazapine.
MitotaneTranylcypromine may increase the orthostatic hypotensive activities of Mitotane.
MoclobemideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Moclobemide.
MoexiprilTranylcypromine may increase the orthostatic hypotensive activities of Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Morphine.
MoxonidineTranylcypromine may increase the hypotensive activities of Moxonidine.
NadololTranylcypromine may increase the orthostatic hypotensive activities of Nadolol.
NaphazolineTranylcypromine may increase the hypertensive activities of Naphazoline.
NateglinideTranylcypromine may increase the hypoglycemic activities of Nateglinide.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Tranylcypromine.
NefazodoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Nefazodone.
NicardipineTranylcypromine may increase the orthostatic hypotensive activities of Nicardipine.
NicotineThe metabolism of Nicotine can be decreased when combined with Tranylcypromine.
NifedipineTranylcypromine may increase the orthostatic hypotensive activities of Nifedipine.
NimodipineTranylcypromine may increase the hypotensive activities of Nimodipine.
NisoldipineTranylcypromine may increase the hypotensive activities of Nisoldipine.
NitroprussideTranylcypromine may increase the hypotensive activities of Nitroprusside.
NorepinephrineTranylcypromine may increase the hypertensive activities of Norepinephrine.
NortriptylineTranylcypromine may increase the serotonergic activities of Nortriptyline.
OctreotideTranylcypromine may increase the hypoglycemic activities of Octreotide.
OlanzapineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Olanzapine.
OlmesartanTranylcypromine may increase the orthostatic hypotensive activities of Olmesartan.
OlodaterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Olodaterol.
OndansetronThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ondansetron.
OrciprenalineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Orciprenaline.
OxycodoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Oxycodone.
OxymetazolineTranylcypromine may increase the hypertensive activities of Oxymetazoline.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tranylcypromine.
PaliperidoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Paliperidone.
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Tranylcypromine.
ParoxetineTranylcypromine may increase the serotonergic activities of Paroxetine.
PasireotideTranylcypromine may increase the hypoglycemic activities of Pasireotide.
PenbutololTranylcypromine may increase the orthostatic hypotensive activities of Penbutolol.
PentamidineTranylcypromine may increase the hypoglycemic activities of Pentamidine.
PerindoprilTranylcypromine may increase the orthostatic hypotensive activities of Perindopril.
PerphenazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Perphenazine.
PethidineTranylcypromine may increase the serotonergic activities of Pethidine.
PhendimetrazineTranylcypromine may increase the hypertensive activities of Phendimetrazine.
PhenelzinePhenelzine may increase the orthostatic hypotensive activities of Tranylcypromine.
PheniramineTranylcypromine may increase the hypertensive activities of Pheniramine.
PhenoxybenzamineTranylcypromine may increase the orthostatic hypotensive activities of Phenoxybenzamine.
PhentermineTranylcypromine may increase the hypertensive activities of Phentermine.
PhentolamineTranylcypromine may increase the orthostatic hypotensive activities of Phentolamine.
PhenylephrineTranylcypromine may increase the hypertensive activities of Phenylephrine.
PholcodinePholcodine may increase the serotonergic activities of Tranylcypromine.
PimozideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pimozide.
PindololTranylcypromine may increase the orthostatic hypotensive activities of Pindolol.
PioglitazoneTranylcypromine may increase the hypoglycemic activities of Pioglitazone.
PiperacetazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Piperacetazine.
PirbuterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pirbuterol.
PirfenidoneThe serum concentration of Pirfenidone can be increased when it is combined with Tranylcypromine.
PizotifenTranylcypromine may increase the anticholinergic activities of Pizotifen.
Potassium ChlorideTranylcypromine may increase the ulcerogenic activities of Potassium Chloride.
PramipexoleTranylcypromine may increase the orthostatic hypotensive activities of Pramipexole.
PramlintidePramlintide may increase the anticholinergic activities of Tranylcypromine.
PrazosinTranylcypromine may increase the orthostatic hypotensive activities of Prazosin.
ProcarbazineTranylcypromine may increase the orthostatic hypotensive activities of Procarbazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Tranylcypromine.
PromazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Promazine.
PromethazineTranylcypromine may increase the orthostatic hypotensive activities of Promethazine.
PropafenoneThe serum concentration of Tranylcypromine can be increased when it is combined with Propafenone.
PropanthelineTranylcypromine may increase the orthostatic hypotensive activities of Propantheline.
PropranololTranylcypromine may increase the orthostatic hypotensive activities of Propranolol.
PropylhexedrineTranylcypromine may increase the hypertensive activities of Propylhexedrine.
ProtriptylineTranylcypromine may increase the serotonergic activities of Protriptyline.
PseudoephedrineTranylcypromine may increase the hypertensive activities of Pseudoephedrine.
QuetiapineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Quetiapine.
QuinaprilTranylcypromine may increase the orthostatic hypotensive activities of Quinapril.
QuinineTranylcypromine may increase the hypoglycemic activities of Quinine.
RacepinephrineTranylcypromine may increase the hypertensive activities of Racepinephrine.
RamiprilTranylcypromine may increase the orthostatic hypotensive activities of Ramipril.
RamosetronTranylcypromine may increase the activities of Ramosetron.
RasagilineTranylcypromine may increase the orthostatic hypotensive activities of Rasagiline.
RemifentanilRemifentanil may increase the serotonergic activities of Tranylcypromine.
RemoxiprideThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Remoxipride.
RepaglinideTranylcypromine may increase the hypoglycemic activities of Repaglinide.
ReserpineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Reserpine.
RimantadineTranylcypromine may increase the orthostatic hypotensive activities of Rimantadine.
RisperidoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Risperidone.
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Tranylcypromine.
RopiniroleTranylcypromine may increase the orthostatic hypotensive activities of Ropinirole.
RosiglitazoneTranylcypromine may increase the hypoglycemic activities of Rosiglitazone.
RotigotineTranylcypromine may increase the orthostatic hypotensive activities of Rotigotine.
SalbutamolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Salbutamol.
SalmeterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Salmeterol.
SaxagliptinTranylcypromine may increase the hypoglycemic activities of Saxagliptin.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Tranylcypromine.
SelegilineTranylcypromine may increase the orthostatic hypotensive activities of Selegiline.
SertindoleThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Sertindole.
SertralineTranylcypromine may increase the serotonergic activities of Sertraline.
SilodosinTranylcypromine may increase the orthostatic hypotensive activities of Silodosin.
SitagliptinTranylcypromine may increase the hypoglycemic activities of Sitagliptin.
SotalolTranylcypromine may increase the orthostatic hypotensive activities of Sotalol.
SpironolactoneTranylcypromine may increase the orthostatic hypotensive activities of Spironolactone.
SufentanilSufentanil may increase the serotonergic activities of Tranylcypromine.
SulfadiazineTranylcypromine may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleTranylcypromine may increase the hypoglycemic activities of Sulfamethoxazole.
SulfisoxazoleTranylcypromine may increase the hypoglycemic activities of Sulfisoxazole.
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Tranylcypromine.
SumatriptanThe metabolism of Sumatriptan can be decreased when combined with Tranylcypromine.
SunitinibTranylcypromine may increase the hypoglycemic activities of Sunitinib.
TacrineThe therapeutic efficacy of Tranylcypromine can be decreased when used in combination with Tacrine.
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Tranylcypromine resulting in a loss in efficacy.
TamsulosinTranylcypromine may increase the orthostatic hypotensive activities of Tamsulosin.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Tranylcypromine.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Tranylcypromine.
TegafurThe serum concentration of the active metabolites of Tegafur can be reduced when Tegafur is used in combination with Tranylcypromine resulting in a loss in efficacy.
TelmisartanTranylcypromine may increase the orthostatic hypotensive activities of Telmisartan.
TerazosinTranylcypromine may increase the orthostatic hypotensive activities of Terazosin.
TerbutalineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Terbutaline.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Tranylcypromine.
TetryzolineTranylcypromine may increase the hypertensive activities of Tetryzoline.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Tranylcypromine.
ThiothixeneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Thiothixene.
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Tranylcypromine.
TimololTranylcypromine may increase the orthostatic hypotensive activities of Timolol.
TiotropiumTranylcypromine may increase the anticholinergic activities of Tiotropium.
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Tranylcypromine.
TolazamideTranylcypromine may increase the hypoglycemic activities of Tolazamide.
TolbutamideTranylcypromine may increase the hypoglycemic activities of Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tranylcypromine.
TopiramateThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Topiramate.
TorasemideTranylcypromine may increase the orthostatic hypotensive activities of Torasemide.
TramadolTramadol may increase the neuroexcitatory activities of Tranylcypromine.
TrandolaprilTranylcypromine may increase the orthostatic hypotensive activities of Trandolapril.
TrazodoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Trazodone.
TriamtereneTranylcypromine may increase the orthostatic hypotensive activities of Triamterene.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Tranylcypromine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Triflupromazine.
TrimethoprimTranylcypromine may increase the hypoglycemic activities of Trimethoprim.
TrimipramineTranylcypromine may increase the serotonergic activities of Trimipramine.
TriprolidineTranylcypromine may increase the hypertensive activities of Triprolidine.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Tranylcypromine.
ValsartanTranylcypromine may increase the orthostatic hypotensive activities of Valsartan.
VenlafaxineTranylcypromine may increase the serotonergic activities of Venlafaxine.
VerapamilTranylcypromine may increase the hypotensive activities of Verapamil.
VilanterolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Vilanterol.
VilazodoneTranylcypromine may increase the serotonergic activities of Vilazodone.
VinblastineTranylcypromine may increase the orthostatic hypotensive activities of Vinblastine.
VincristineTranylcypromine may increase the orthostatic hypotensive activities of Vincristine.
VortioxetineTranylcypromine may increase the serotonergic activities of Vortioxetine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ziprasidone.
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Tranylcypromine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Zuclopenthixol.
Food Interactions
  • Avoid aged foods (chesse, red wine), pickled foods, cured foods (bacon/ham), chocolate, fava beans, beer, unless approved by your physician.
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (caffeine).
  • Avoid St. John's Wort.

Targets

1. Amine oxidase [flavin-containing] A

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Amine oxidase [flavin-containing] A P21397 Details

References:

  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  2. Volz HP, Gleiter CH: Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs Aging. 1998 Nov;13(5):341-55. Pubmed
  3. Shioda K, Nisijima K, Yoshino T, Kato S: Mirtazapine abolishes hyperthermia in an animal model of serotonin syndrome. Neurosci Lett. 2010 Jul 23. Pubmed
  4. Gatch MB, Taylor CM, Flores E, Selvig M, Forster MJ: Effects of monoamine oxidase inhibitors on cocaine discrimination in rats. Behav Pharmacol. 2006 Mar;17(2):151-9. Pubmed
  5. Lang W, Masucci JA, Caldwell GW, Hageman W, Hall J, Jones WJ, Rafferty BM: Liquid chromatographic and tandem mass spectrometric assay for evaluation of in vivo inhibition of rat brain monoamine oxidases (MAO) A and B following a single dose of MAO inhibitors: application of biomarkers in drug discovery. Anal Biochem. 2004 Oct 1;333(1):79-87. Pubmed
  6. Shioda K, Nisijima K, Yoshino T, Kato S: Extracellular serotonin, dopamine and glutamate levels are elevated in the hypothalamus in a serotonin syndrome animal model induced by tranylcypromine and fluoxetine. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jul;28(4):633-40. Pubmed
  7. Salsali M, Holt A, Baker GB: Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol. 2004 Feb;24(1):63-76. Pubmed
  8. Nolen WA: [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression] Ned Tijdschr Geneeskd. 2003 Oct 4;147(40):1940-3. Pubmed
  9. Cohen C, Curet O, Perrault G, Sanger DJ: Reduction of oral ethanol self-administration in rats by monoamine oxidase inhibitors. Pharmacol Biochem Behav. 1999 Nov;64(3):535-9. Pubmed
  10. Wiest SA, Steinberg MI: 3H[2-(2-benzofuranyl)-2-imidazoline] (BFI) binding in human platelets: modulation by tranylcypromine. Naunyn Schmiedebergs Arch Pharmacol. 1999 Aug;360(2):209-16. Pubmed
  11. Loscher W, Lehmann H, Teschendorf HJ, Traut M, Gross G: Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy. J Pharmacol Exp Ther. 1999 Mar;288(3):984-92. Pubmed
  12. Todd KG, Baker GB: GABA-elevating effects of the antidepressant/antipanic drug phenelzine in brain: effects of pretreatment with tranylcypromine, (-)-deprenyl and clorgyline. J Affect Disord. 1995 Dec 13;35(3):125-9. Pubmed
  13. Finberg JP, Youdim MB: Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology. 2002 Dec;43(7):1110-8. Pubmed

2. Amine oxidase [flavin-containing] B

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Amine oxidase [flavin-containing] B P27338 Details

References:

  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  2. Volz HP, Gleiter CH: Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs Aging. 1998 Nov;13(5):341-55. Pubmed
  3. Shioda K, Nisijima K, Yoshino T, Kato S: Mirtazapine abolishes hyperthermia in an animal model of serotonin syndrome. Neurosci Lett. 2010 Jul 23. Pubmed
  4. Gatch MB, Taylor CM, Flores E, Selvig M, Forster MJ: Effects of monoamine oxidase inhibitors on cocaine discrimination in rats. Behav Pharmacol. 2006 Mar;17(2):151-9. Pubmed
  5. Lang W, Masucci JA, Caldwell GW, Hageman W, Hall J, Jones WJ, Rafferty BM: Liquid chromatographic and tandem mass spectrometric assay for evaluation of in vivo inhibition of rat brain monoamine oxidases (MAO) A and B following a single dose of MAO inhibitors: application of biomarkers in drug discovery. Anal Biochem. 2004 Oct 1;333(1):79-87. Pubmed
  6. Shioda K, Nisijima K, Yoshino T, Kato S: Extracellular serotonin, dopamine and glutamate levels are elevated in the hypothalamus in a serotonin syndrome animal model induced by tranylcypromine and fluoxetine. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jul;28(4):633-40. Pubmed
  7. Salsali M, Holt A, Baker GB: Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol. 2004 Feb;24(1):63-76. Pubmed
  8. Nolen WA: [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression] Ned Tijdschr Geneeskd. 2003 Oct 4;147(40):1940-3. Pubmed
  9. Cohen C, Curet O, Perrault G, Sanger DJ: Reduction of oral ethanol self-administration in rats by monoamine oxidase inhibitors. Pharmacol Biochem Behav. 1999 Nov;64(3):535-9. Pubmed
  10. Wiest SA, Steinberg MI: 3H[2-(2-benzofuranyl)-2-imidazoline] (BFI) binding in human platelets: modulation by tranylcypromine. Naunyn Schmiedebergs Arch Pharmacol. 1999 Aug;360(2):209-16. Pubmed
  11. Loscher W, Lehmann H, Teschendorf HJ, Traut M, Gross G: Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy. J Pharmacol Exp Ther. 1999 Mar;288(3):984-92. Pubmed
  12. Todd KG, Baker GB: GABA-elevating effects of the antidepressant/antipanic drug phenelzine in brain: effects of pretreatment with tranylcypromine, (-)-deprenyl and clorgyline. J Affect Disord. 1995 Dec 13;35(3):125-9. Pubmed
  13. Finberg JP, Youdim MB: Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology. 2002 Dec;43(7):1110-8. Pubmed

Enzymes

1. Cytochrome P450 3A4

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 2D6

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2D6 P10635 Details

References:

  1. Salsali M, Holt A, Baker GB: Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol. 2004 Feb;24(1):63-76. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

3. Cytochrome P450 2C9

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2C9 P11712 Details

References:

  1. Salsali M, Holt A, Baker GB: Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol. 2004 Feb;24(1):63-76. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

4. Cytochrome P450 2C19

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2C19 P33261 Details

References:

  1. Stadel R, Yang J, Nalwalk JW, Phillips JG, Hough LB: High-affinity binding of [3H]cimetidine to a heme-containing protein in rat brain. Drug Metab Dispos. 2008 Mar;36(3):614-21. Epub 2007 Dec 19. Pubmed
  2. Salsali M, Holt A, Baker GB: Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol. 2004 Feb;24(1):63-76. Pubmed
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

5. Cytochrome P450 1A2

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 1A2 P05177 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

6. Cytochrome P450 2E1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2E1 P05181 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

7. Cytochrome P450 2A6

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2A6 P11509 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on January 06, 2014 09:20